

CONSOLIDATED RESULTS			Particulars	STANDALONE		
Quarter Ended on 30th June 2009 (Reviewed)	Quarter Ended on 30th June 2008 (Reviewed)	Previous Accounting year ended on 31st March 2009 (Audited)		Quarter Ended on 30th June 2009 (Reviewed)	Quarter Ended on 30th June 2008 (Reviewed)	Previous Accounting year ended on 31st March 2009 (Audited)
			1 (a) Net Sales / Income from Operations			
15852	12227	67831	Domestic	15852	12227	67831
13397	11413	45536	Exports	7296	11413	44126
29249	23640	113367	Total	23148	23640	111957
185	706	1761	Less : Excise Duty	185	706	1761
29064	22934	111606	Net Sales / Income from Operations	22963	22934	110196
44	103	410	(b) Other Operating Income	44	103	410
29108	23037	112016	Total Income	23007	23037	110606
			2 Expenditure			
956	(2765)	(3073)	(a) Decrease/(increase) in stock in trade and work in progress	956	(2765)	(3073)
6162	11181	43313	(b) Consumption of Raw Materials & Packing Materials	6162	11181	43313
8377	3562	14876	(c) Purchase of traded goods	3540	3562	13861
3284	2790	13169	(d) Employees' Cost	3284	2790	13169
923	852	4030	(e) Research and Development Expense	923	852	4030
62	291	788	(f) Excise Duty	62	291	788
6293	4781	25979	(g) Other Expenditure	6252	4781	25966
26057	20692	99082	Total	21179	20692	98054
3051	2345	12934	3 Profit from Operations before Other Income, Interest, Depreciation Foreign Exchange gain / (loss) & Exceptional Items	1828	2345	12552
25	25	104	4 Other Income	25	25	104
3076	2370	13038	5 Profit/(Loss) before Interest, Depreciation, Foreign Exchange gain / (loss) & Exceptional Items	1853	2370	12656
1042	890	3831	6 Depreciation	1042	890	3831
808	963	4006	7 Interest (Net)	808	963	4006
1226	517	5201	8 Profit/(Loss) after Interest but before Foreign Exchange gain / (loss) & Exceptional Items	3	517	4819
-	(1049)	(3536)	9 Foreign Exchange gain / (loss) (Net)	-	(1049)	(3507)
1226	(532)	1665	10 Profit / (Loss) before Exceptional Items	3	(532)	1312
-	-	752	11 Exceptional Items Less : Provision for Diminution in Investment	-	-	752
1226	(532)	913	12 Net Profit / (Loss) from Ordinary Activities before Tax	3	(532)	560
-	35	220	13 Tax Expense Less : Provision for Fringe Benefit Tax & Wealth Tax	-	35	220
1	-	50	Less : Provision for Current Tax	1	0	50
-	-	(3)	Less/(Add) : Provision for Deferred Tax Liability/(Assets)	-	0	(3)
-	97	436	Add : Provision of Income Tax of earlier years written back (Net)	-	97	436
1225	(470)	1082	14 Net Profit / (Loss) from Ordinary Activities after Tax	2	(470)	729
2729	2769	2744	15 Paid up Equity Share Capital (Face value of share Rs 2/-)	2729	2769	2744
		30309	16 Reserves excluding Revaluation Reserve			29955
0.89	(0.34)	0.78	17 Earnings Per Share (EPS) Basic & Diluted EPS (Not Annualised)	-	(0.34)	0.53
51705496	53701900	52439181	18 Public Shareholding - Number of Shares	51705496	53701900	52439181
37.89	38.79	38.22	- Percentage of Shareholding	37.89	38.79	38.22
			19 Promoters and Promoter Group Shareholding			
22250000		22250000	(a) Pledged / Encumbered Number of Shares	22250000		22250000
26.25		26.25	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	26.25		26.25
16.31		16.22	Percentage of Shares (as a % of the total share capital of the Company)	16.31		16.22
62503005		62503005	(b) Non - Encumbered Number of Shares	62503005		62503005
73.75		73.75	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	73.75		73.75
45.80		45.56	Percentage of Shares (as a % of the total share capital of the Company)	45.80		45.56

Notes :

- 1 The above results, which includes unreviewed results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors.
- 2 The Company is engaged in Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS - 17)
- 3 As on 30/06/2009, the Company has bought back 21,21,882 equity shares(subject to close out) at an average price of Rs.35.28 for a total consideration of Rs.748.70 lacs which is about 22.69% of the total buy-back size of Rs.3300 lacs. In terms of provisions of Section 77A of the Companies Act, 1956 and SEBI(Buy-back of Securities) Act, 1998, the Company has extinguished 19,96,404 equity shares on or before 30/06/2009 and the balance equity shares were extinguished on or before 21/07/2009.
- 4 Provision for Current Tax (MAT) and Fringe Benefit Tax has been made in accordance with the proposals contained in Finance Bill (No 2) of 2009.
- 5 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the Listing Agreement. The Standalone Financial Results are available on the company's website viz. www.alembic-india.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 6 Details of Investors' Complaints for the quarter ended on 30th June, 2009 : Unresolved at the beginning of the quarter-NIL Received during the quarter-7, Disposed off during the quarter-7 , Unresolved at the end of the quarter - NIL.
- 7 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Place : Vadodara
Date : 28th July, 2009

Chirayu Amin